HDV Overview
Robert G Gish MD, Professor Consultant, Stanford University

Eiger’s Approach for an HDV Cure
Eduardo B. Martins, MD, DPhil SVP, Liver and Infectious Diseases

Drug Development Role of Immune System in HBV Cure: Innate and Adaptive Immunity
Adam J. Gehring, Ph.D., Assistant Professor, Department of Immunology, University of Toronto

Immune Targeting – RIGI Agonist SB 9200
Nezam H. Afdhal MD, DSc

HBV Virology - Novel Targets
Professor Stephen Locarnini

ALN-HBV
Laura Sepp-Lorenzino

RNAi in HBV–Learnings from the Arrowhead Program

HBV Cure: Insights for the Biotechnology and the Research Analyst Community 
Lalo Flores, PhD

Hepatitis Research and Development Combination Strategies
Prof. Henry LY Chan, The Chinese University of Hong Kong

Arbutus’s HBV Combination Therapy Approach
Dr. Michael J. Sofia, Chief Scientific Officer

HBV Cure – Definition and New Drugs in Development
Harry L.A. Janssen, University of Toronto, Canada